PSNL

Personalis is a pre-inflection cancer-genomics story trading like it has already inflected. FY2025 revenue fell 17.7% to $69.6M, and while management credibly attributes most of that to the one-off wind-down of the Natera Enterprise project (Enterprise revenue collapsed from $25.4M to $5.9M), the result is a company shrinking, not scaling, at a 20.7x price-to-sales multiple. Profitability is deeply negative — operating margin of -126%, a -$81.3M net loss, and -$88.1M operating income that actually widened 29% — and the five-year history shows no path to break-even yet: cumulative losses have driven retained earnings to -$631M. This is a business consuming capital to buy future revenue it has not yet booked.

The balance sheet buys time but not comfort. Equity of $261M and liabilities/equity of just 0.28x mean there is no debt-driven solvency risk, and current assets of $268M against $39.6M current liabilities is healthy near-term. But operating cash flow was -$74.9M (a 66% deterioration) against only $124M of cash. That is roughly 1.5–2 years of runway at the current burn, and shares already grew 18.5% in a single year — so further dilution to fund the MRD build-out is the base case, not a tail risk. At today's valuation, dilution directly erodes per-share value.